PRPeptide Evidence ReferenceEVIDENCE-GRADED · EDUCATIONAL
Educational reference only — not medical advice. Nothing is sold on this site. Research compounds are not for human use.
Home>>Peptides>>CJC-1295 + Ipamorelin
Minimal evidence WADA prohibitedGH / growth factors

CJC-1295 + Ipamorelin

A widely marketed combination of a GHRH analog with a ghrelin-receptor agonist, intended to stimulate GH release through both regulatory pathways. The pairing has never been tested in a published trial.

CompoundCJC-1295 + Ipamorelin
CategoryVendor blend (GH secretagogues)
ClassGrowth Hormone and Growth Factors
Evidence tierMinimal evidence
WADA statusProhibited in sport (or falls under a prohibited class) — see the WADA reference table
Sold on this siteNo — this is a reference database

Overview

This entry covers CJC-1295 + Ipamorelin, a vendor blend (gh secretagogues), graded "Minimal evidence" in this catalog's evidence system. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

A widely marketed combination of a GHRH analog with a ghrelin-receptor agonist, intended to stimulate GH release through both regulatory pathways. The pairing has never been tested in a published trial.

Mechanism of Action

The rationale stacks GHRH-receptor stimulation with ghrelin-receptor stimulation — the two physiological levers of GH secretion — with the hypothesis that pulses become larger and more natural.

Research and Evidence

No published study evaluates the combination in humans; component evidence is limited to separate early-phase pharmacology.

Evidence in context: the Growth Hormone and Growth Factors class page collects the shared evidence themes and study-reading guidance for this category.

Safety and Side Effects

Two unapproved secretagogues at an unspecified ratio; prohibited in sport.

Educational notice: this entry describes published research and, where they exist, regulator labels. It is not medical advice and not a recommendation for use. Research-grade compounds have no verified human-safety data.

Frequently Asked Questions

What is the evidence tier of CJC-1295 + Ipamorelin?

CJC-1295 + Ipamorelin is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.

Is CJC-1295 + Ipamorelin an approved medicine?

No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.

Where can I read the primary studies for CJC-1295 + Ipamorelin?

The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.

References

  1. ClinicalTrials.gov — no combination trials registered. [source]
  2. WADA Prohibited List. [source]
EM
Dr. Elena Marsh, PhDMolecular Pharmacology · Lead Editor

Written and maintained by the editorial team. Medically reviewed by Dr. James Okafor, MD (Internal Medicine).

Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.

Advertisement